文献速递呼吸危重症与机械通气呼吸道感染

预防性米诺环素用于危重症患者谵妄:一项随机对照试验

Prophylactic Minocycline for Delirium in Critically Ill Patients: A Randomized Controlled Trial.
PubMed 文献 · Chest · 2023-12-01

这项在四个ICU开展的随机、安慰剂对照、双盲试验,将160例成人危重症患者随机分配接受米诺环素(100 mg,每日两次)或安慰剂,最终分析159例(米诺环素组84例,安慰剂组75例)。作者认为该较小样本研究提示米诺环素对谵妄发生率可能有积极作用,需进一步研究确认。

核心结论

  • 在这项较小样本研究中,预防性米诺环素可能降低危重症患者谵妄发生率,但需进一步研究确认其预防获益。

研究设计与样本

  • 随机、安慰剂对照、双盲试验,在四个ICU开展,纳入18岁及以上危重症患者。
  • 共随机160例,安慰剂组1例在治疗前死亡,最终分析159例(米诺环素组84例,安慰剂组75例)。
  • 干预为米诺环素100 mg每日两次或安慰剂;主要结局为28天内或ICU出院前谵妄发生率。

主要发现

  • 其他谵妄相关结局(谵妄天数、无谵妄/昏迷天数、机械通气时长、ICU住院时长、ICU死亡率)未受米诺环素治疗影响。

临床怎么用

  • 该研究提示米诺环素可能作为危重症患者谵妄的预防性措施,但证据尚不充分,需进一步验证后方可常规推荐。

局限性

  • 研究样本量较小(最终分析159例),作者指出需进一步研究确认获益。
  • COVID-19大流行后决定提前终止患者入组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Delirium is a potentially severe form of acute encephalopathy. Minocycline has neuroprotective effects in animal models of neurologic diseases; however, data from human studies remain scarce. RESEARCH QUESTION: Does the neuroprotective effect of minocycline prevent delirium occurrence in critically ill patients? STUDY DESIGN AND METHODS: This study was a randomized, placebo-controlled, double-anonymized trial conducted in four ICUs. Patients aged 18 years or older were eligible and randomized to receive minocycline (100 mg, twice daily) or placebo. The primary outcome was delirium incidence within 28 days or before ICU discharge. Secondary outcomes included days in delirium during ICU stay, delirium/coma-free days, length of mechanical ventilation, ICU length of stay, ICU mortality, and hospital mortality. The kinetics of various inflammatory (IL-1β, IL-6, IL-10, and C-reactive protein) and brain-related biomarkers (brain-derived neurotrophic factor and S100B) were used as exploratory outcomes. RESULTS: A total of 160 patients were randomized, but one patient in the placebo group died before treatment; thus the data from 159 patients were analyzed (minocycline, n = 84; placebo, n = 75). After the COVID-19 pandemic it was decided to stop patient inclusion early. There was a small but significant decrease in delirium incidence: 17 patients (20%) in the minocycline arm compared with 26 patients (35%) in the placebo arm (P = .043). No other delirium-related outcomes were modified by minocycline treatment. Unexpectedly, there was a significant decrease in hospital mortality (39% vs. 23%; P = .029). Among all analyzed biomarkers, only plasma levels of C-reactive protein decreased significantly after minocycline treatment (F = 0.75, P = .78, within time; F = 4.09, P = .045, group × time). INTERPRETATION: Our findings in this rather small study signal a possible positive effect of minocycline on delirium incidence. Further studies are needed to confirm the benefits of this drug as a preventive measure in critically ill patients. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov; No.: NCT04219735; URL: www. CLINICALTRIALS: gov.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Dal-Pizzol F, Coelho A, Simon CS, et al. Prophylactic Minocycline for Delirium in Critically Ill Patients: A Randomized Controlled Trial. Chest. 2023. PMID: 38043911. doi:10.1016/j.chest.2023.11.041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。